Pharsight

Eysuvis generic

Eysuvis is an ophthalmic drug owned by Alcon Labs Inc. This drug, which contains the active ingredient loteprednol etabonate, was first authorized for market use on October 26, 2020. Eysuvis, available in suspension/drops dosage forms, holds a total of 2 patents.

When will Eysuvis generic be available?

The generic version of Eysuvis could possibly be available after May 3, 2033. This date coincides with the expiry of the last patent held by Alcon Labs Inc. for Eysuvis. The patents, including those titled 'Nanocrystals, compositions, and methods that aid particle transport in mucus' and 'Compositions and methods for ophthalmic and/or other applications', expire on the same day.

Eysuvis uses

Eysuvis is primarily used for the treatment of dry eye in patients. Its effectiveness is derived from loteprednol etabonate, the active ingredient that targets and alleviates the symptoms associated with this condition.

Eysuvis patent expiration

Eysuvis, made by Alcon Labs Inc., has two patents protecting it, both expiring on May 3, 2033. Once these patents expire, the market could see the release of Eysuvis generic versions. Below are the details of the patent:

Eysuvis dosage

Want to ask something?